アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Case study: A custom RabMAb® solution for detection of subtle epitope differences in amyloid beta peptides in Alzheimer’s disease research
Dr. Pankaj D. Mehta, an investigator at the New York Institute for Basic Research in Developmental Disabilities, has been studying Abeta peptides in the context of Alzheimer's disease (AD) for a number of years.
Early on, any commercially available antibodies to these peptides were either incapable of differentiating between closely related forms (such as Abeta 1-40 and Abeta 1-42) or were “not sensitive enough to quantitate small amounts of peptide present in body fluids,” explained Dr. Mehta.
Having seen colleagues attempt and fail to create specific mouse monoclonal antibodies to Abeta isoforms, Dr. Mehta knew he would need another approach and turned to Abcam’s RabMAb® technology.
“The RabMAb® products I received are specific to an immunogen with no cross-reactivity to other peptides or proteins and possess higher affinity than mouse monoclonal antibodies.”
-Dr. Pankaj D. Mehta, Institute for Basic Research in Developmental Disabilities (NY) (Pankaj.Mehta@opwdd.ny.go)
Following his extensive efforts to induce sufficient immune responses, together Dr. Mehta and Abcam were successful in generating rabbit monoclonals to Abeta peptides. The key differentiator was the ability of these antibodies to detect the small differences between the various forms of amyloid beta.
Dr. Mehta sat down with Abcam to discuss the field of Alzheimer's disease, the role Abeta plays, as well as the solution RabMAb® technology is able provide in research applications. The entire case study is available for viewing or download below.